Intracystic papillary carcinoma of the breast (ICP) is a rare form of noninvasive breast cancer. The average age of onset is 65 years. Patients with ICP have a greater than 15-year survival rate advantage compared to patients with other breast carcinomas. There have been no reports of disease-related deaths in patients with ICP and no increased risk of disease in the contralateral breast. No definitive conclusions have been made regarding adjuvant treatment; however, ICP should generally be treated like ductal carcinoma in situ (DCIS). Tamoxifen is often recommended.